Information Provided By:
Fly News Breaks for April 12, 2016
REGN
Apr 12, 2016 | 06:57 EDT
Brean Capital analyst Jason Wittes views Regeneron's licensing and collaboration deal with Intellia Therapeutics as a "relatively cheap" way for the company to diversify into gene therapy. Wittes keeps a $489 price target on Regeneron and reiterates a Buy rating on the shares.
News For REGN From the Last 2 Days
There are no results for your query REGN